3.22
+0.025(+0.78%)
Currency In USD
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
4766
First IPO Date
February 05, 2004
| Name | Title | Pay | Year Born |
| Dr. Christian Wojczewski Ph.D. | Chief Executive Officer & Management Board Member | 1.23M | 1973 |
| Dr. Ian M. Hunneyball | Senior Vice President of Programme Management & Clinical Operations | 133,655 | 1950 |
| Ms. Aurelie Dalbiez | Chief People Officer & Member of Management Board | 540,382 | 1977 |
| Dr. Cord Dohrmann Ph.D. | Chief Scientific Officer & Member of Management Board | 576,100 | 1964 |
| Dr. Christian Dargel | EVice President Global Head of Legal & Compliance | 0 | 1971 |
| Dr. David Hallet | Executive Vice President | 0 | N/A |
| Ms. Christiane Honisch | SVice President Head of Diagnostics | 0 | N/A |
| Uwe Andag | EVice President Head of Metabolic Diseases | 0 | N/A |
| Mr. Volker Braun | Executive Vice President and Head of Global Investor Relations & ESG | 0 | N/A |
| Mr. Paul Hitchin | Chief Financial Officer & Member of Management Board | 0 | N/A |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
